Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Vir Biotechnology Inc (NASDAQ: VIR) closed at $8.13 in the last session, up 0.37% from day before closing price of $8.10. In other words, the price has increased by $0.37 from its previous closing price. On the day, 0.77 million shares were traded. VIR stock price reached its highest trading level at $8.29 during the session, while it also had its lowest trading level at $8.08.
Ratios:
We take a closer look at VIR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.05 and its Current Ratio is at 9.05. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 03 ’24 when De Backer Marianne sold 72,995 shares for $9.46 per share. The transaction valued at 690,365 led to the insider holds 678,457 shares of the business.
HANLY ANN M. sold 2,711 shares of VIR for $27,251 on Apr 01 ’24. The EVP & Chief Technology Officer now owns 132,069 shares after completing the transaction at $10.05 per share. On Mar 27 ’24, another insider, Lee Sung, who serves as the EVP & Chief Financial Officer of the company, sold 6,008 shares for $9.89 each. As a result, the insider received 59,404 and left with 100,492 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 1104411776 and an Enterprise Value of -304107616. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.74 while its Price-to-Book (P/B) ratio in mrq is 0.69. Its current Enterprise Value per Revenue stands at -3.529 whereas that against EBITDA is 0.475.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $27.48, while it has fallen to a 52-week low of $7.72. The 50-Day Moving Average of the stock is -19.15%, while the 200-Day Moving Average is calculated to be -24.98%.
Shares Statistics:
According to the various share statistics, VIR traded on average about 1.09M shares per day over the past 3-months and 864050 shares per day over the past 10 days. A total of 134.78M shares are outstanding, with a floating share count of 88.44M. Insiders hold about 34.50% of the company’s shares, while institutions hold 53.41% stake in the company. Shares short for VIR as of 1711584000 were 4957797 with a Short Ratio of 4.57, compared to 1709164800 on 5079101. Therefore, it implies a Short% of Shares Outstanding of 4957797 and a Short% of Float of 6.17.
Earnings Estimates
The market rating for Vir Biotechnology Inc (VIR) is a result of the insights provided by 7.0 analysts actively involved in the assessment.On average, analysts expect EPS of -$1.05 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.32, while EPS last year was -$1.06. The consensus estimate for the next quarter is -$1.04, with high estimates of -$0.91 and low estimates of -$1.23.
Analysts are recommending an EPS of between -$3.43 and -$4.94 for the fiscal current year, implying an average EPS of -$4.1. EPS for the following year is -$3.98, with 9.0 analysts recommending between -$2.84 and -$5.66.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $11.71M. It ranges from a high estimate of $39.4M to a low estimate of $2.57M. As of the current estimate, Vir Biotechnology Inc’s year-ago sales were $50.1MFor the next quarter, 6 analysts are estimating revenue of $9.06M. There is a high estimate of $21.3M for the next quarter, whereas the lowest estimate is $4.79M.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $121.8M, while the lowest revenue estimate was $19.71M, resulting in an average revenue estimate of $40.52M. In the same quarter a year ago, actual revenue was $86.18MBased on 8 analysts’ estimates, the company’s revenue will be $41.61M in the next fiscal year. The high estimate is $106.2M and the low estimate is $17.69M.
